Company ProfilePremium

Peking University Resources (Holdings) Company Limited

Company Profile Analysis

Ticker: 0618.HK北大資源

ESOMAR 23 Corporate BadgeISO Certifications Badge
Peking University Resources (Holdings) Company Limited - Company showcase

Year Founded & Workforce

1991

512 Employees

Peking University Resources (Holdings) Company Limited logo

Peking University Resources (Holdings) Company Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Peking University Resources (Holdings) Company Limited Overview

Peking University Resources is a small-cap, Bermuda-domiciled, Hong Kong-listed holding company. It is part-way through a deliberate exit from Chinese residential property development, which was its dominant business from 2013 to 2024. That business collapsed under default litigation, guarantee claims and the 2020 bankruptcy reorganisation of its former parent, Peking University Founder Group. In August 2025 the company placed its last property-development subsidiaries into an off-balance-sheet partnership. This deconsolidated defaulted loans and guarantee provisions and produced a one-off RMB1.65 billion profit in FY2026. What remains is a sub-scale portfolio of four activities: an e-commerce brand-operation and distribution business (60% of FY2026 revenue); the "Ye Kai Tai" traditional-Chinese-medicine pharmacy chain in Wuhan; a run-off property-leasing book; and an SFC-licensed special-situations asset-management subsidiary. In July 2026 the company also announced two acquisitions in Tanzania (aluminium extrusion and lead-battery recycling). The equity case rests on whether management can turn a cleaned-up balance sheet into recurring operating profit. So far it has not.


Company's own description (FY2026 Annual Report, Company Profile)

The FY2026 annual report says the Group is principally engaged in four activities in Mainland China, Singapore and Hong Kong:

  • medical and pharmaceutical retail;

  • e-commerce and distribution;

  • property development;

  • property investment and management.

As at 31 March 2026 the pharmacies, which trade under the "Yekaitai (葉開泰)" brand, comprised:

  • 38 retail pharmacies;

  • 15 TCM clinics;

  • 1 beauty clinic;

  • 1 dermatology clinic;

  • an online pharmacy.

The e-commerce and distribution business sells consumer electronics, health food and other products through Douyin, JD.com and other distributors. The property investment business leases unsold completed properties. Through a subsidiary holding an SFC Type 9 (asset management) licence, the Group also runs a special-opportunities asset-management business.

Independent characterisation

Economically, the group is now three things:

  1. A low-margin e-commerce "TP" operator and distributor. It is a brand partner and channel operator for domestic brands such as Joyoung, Huawei, Xiaomi, Jinlongyu and Aodong. It runs stores and content campaigns across JD.com, Tmall/Taobao, Pinduoduo, Vipshop, Douyin, Xiaohongshu, Kuaishou and WeChat Channels.

    • Revenue is recognised mostly on a gross basis from product sales.

    • Segment profit margin was 3.2% in FY2026, which is consistent with distribution rather than fee-based TP economics.

    • This business descends from the group's legacy IT-products distribution arm (EC-Founder heritage). That arm was largely dismantled in FY2023–FY2024 after litigation from Peking Founder and a creditor.

  2. A regional TCM-oriented pharmacy chain. Ye Kai Tai is a roughly 400-year-old Wuhan brand recognised as a "China Time-honored Brand" (中華老字號) in 1994. It was acquired in two steps (August and November 2023) for a total of RMB81m. The chain is shrinking: 56 stores at March 2024, 47 at March 2025 and 38 at March 2026. It lost RMB54.7m in FY2026, including a RMB38.6m goodwill impairment.

  3. A property run-off and special-situations vehicle.

    • About 284,300 sqm of completed properties remained held for sale at 31 March 2026.

    • Investment properties are still being sold down.

    • The Type 9 licensed subsidiary has so far mainly managed vehicles tied to the group's own distressed property assets, including the partnership that absorbed the property-development subsidiaries.

Revenue model mix (FY2026)

Revenue typeSegmentFY2026 revenue (CNY Mn)Share of group (%)Model
Product sales (gross)E-commerce and distribution936.160.3Transactional / distribution
Pharmaceutical retail plus medical/consultation servicesMedical and pharmaceutical retail155.110.0Retail plus service fees
Property sales (delivery-based)Property development377.324.3One-off, non-recurring (run-off)
Rental and property management feesProperty investment and management83.05.3Recurring lease (shrinking)
Total—1,551.5100.0—

There is no subscription or licensing revenue. Asset-management fee income is not separately disclosed and appears immaterial.

Value-chain position, customers and end-markets

SegmentValue-chain positionCustomer typeEnd-market
E-commerce and distributionMid-stream brand operator / distributor between manufacturers and platformsConsumers (B2C via platforms) and distributors (B2B)China online retail: consumer electronics, small appliances, health food
Pharma retailDownstream retail and primary TCM careRetail patients, medical-insurance-settled purchasesChina retail pharmacy and TCM services (Wuhan focus); Singapore (minor); Dubai (ResoHealth, early stage)
Property developmentDeveloper (now run-off)HomebuyersChina residential (Tier-2/3 cities)
Property investmentLandlord / property managerCommercial tenantsChina commercial leasing
Asset managementSpecial-situations GP / managerInstitutional LPs (partners in group-related vehicles)China real-estate NPAs; stated interest in healthcare and technology

Strategy

Stated strategic themes (FY2026 Chairman's Statement and MD&A)

  • The company describes a completed "key strategic realignment": the August 2025 partnership "effectively eliminating historical risks" and leaving the group with no property projects under development.

  • The guiding philosophy is "prudent operations and innovative development", aligned with the national 15th Five-Year Plan (2026–2030) on the digital economy and healthcare.

E-commerce: refine the omnichannel system, deepen digitalisation, upgrade the supply chain, explore cross-border e-commerce, and build a dual engine of "e-commerce operations + health products", including possible own-brand health products.

Pharma: accelerate the "pharmacies + TCM consultations + digital health" model; integrate medical resources and specialised clinics; pursue AI-enabled service; expand digital healthcare globally (Dubai).

Property: orderly leasing and disposal of completed assets to generate cash for the core businesses.

Asset management: prudently develop special-opportunity asset investment, including in technology-related industries.

Initiatives announced in the last 24 months (October 2024 to October 2026)

DateInitiativeTypeStatus
7 May 2025Partnership with Suzhou Aoze and Chongqing Jingjiahui; injection of On Tai groupRestructuring / deleveragingCompleted 11 Aug 2025
FY2026Store rationalisation; new Wuhan TCM clinic + pharmacy complexOperationalOngoing (38 stores)
Oct 2025"Ye Kai Tai Health" AI appDigital platformLaunched
FY2026ResoHealth FZCO, Dubai; LetsGo digital-health platformNew business / geographic expansionEarly stage
9 Jan 2026Trivitron Digital AI digital-health programme with Trivitron HealthcarePartnershipAnnounced
30 Mar 2026JV with Shanghai Cun'an and Mr Feng for non-ferrous metals international trade and supply chainNew businessTerminated 29 Jul 2026 before capital injection
29 Jul 2026Acquisition of Tanzanian aluminium extruder and lead-battery recycler (US$6.59m)Diversification M&APending (registration within 3 months)
FY2025–FY2026Disposal of residual property-investment entities (Hangzhou Linghangxing, Chongqing Yuefeng, Tianjin Ruihesheng)Portfolio clean-upCompleted

Cost programmes and targets

  • Selling, distribution and administrative expenses fell 27% in FY2026 to RMB259.5m, attributed to deconsolidation and streamlining.

  • Headcount fell from 735 to 512.

  • No quantified cost-saving targets have been published.

Medium-term financial targets and guidance

None published. The company provides no revenue, margin or return guidance. Its only forward-looking financial communication in the period was the 17 June 2026 positive profit alert (RMB1.4–1.8bn profit for FY2026), which the actual result of RMB1.645bn fell within.

Analyst view on strategic coherence. The last 24 months show a pattern of opportunistic, loosely connected initiatives: AI health apps, a Dubai health subsidiary, an Indian medtech partnership, a metals-trading JV abandoned within four months, and East African aluminium and lead-battery assets. None is clearly related to the stated e-commerce and TCM core, and none comes with disclosed capital budgets or return targets. This is the main strategic weakness after the balance-sheet clean-up.

Products & Services

Medical and pharmaceutical retail

OfferingDescription / capabilitiesTarget customerLaunch / statusPricing model
Ye Kai Tai retail pharmacies38 stores (31 Mar 2026), down from 47 (Mar 2025) and 56 (Mar 2024); Wuhan-centred; OTC, prescription and TCM productsWuhan residents; medical-insurance-settled buyersBrand history approx. 400 years; acquired 2023Retail margin
Ye Kai Tai TCM clinics15 clinics (Mar 2026), up from 11 (Mar 2025) and 5 (Mar 2024); TCM diagnosis, acupuncture, massage, physiotherapy, herbal prescriptionsChronic-condition and wellness patientsExpansion since Aug 2023 under the "pharmacy + TCM" modelConsultation fees plus herbal/drug sales
TCM clinic + pharmacy complex (Wuhan)New flagship-format integrated outletSameAdded FY2026Same
Beauty clinic1 clinicAesthetic consumersDisclosed FY2026Service fees
Dermatology clinic1 clinicDermatology patientsDisclosed FY2026Service fees
Online pharmacy (B2C) and O2O instant deliveryPlatform-based online drug retail and instant deliveryOnline consumersExpanded FY2025–FY2026Retail margin
"Ye Kai Tai Health" appAI and big-data platform: intelligent consultation, syndrome differentiation and medication recommendation, health management, drug delivery; membership and WeChat private-traffic operationsMembers / repeat customersLaunched Oct 2025—
ResoHealth FZCO / LetsGo platform (Dubai)AI-driven corporate health management: prevention, screening, management, interventionEmployers, insurers, medical institutions in Dubai and the Middle EastEstablished FY2026—
Trivitron Digital AI programmeDigital-health programme launched with Trivitron Healthcare (voluntary announcement 9 Jan 2026)—Jan 2026—
Singapore operationsSmall pharma/medical revenue (RMB9.1m in FY2024)Singapore customersFY2024—

E-commerce and distribution

OfferingDescriptionPartner brands / platformsPricing model
Brand self-operationGroup-operated online stores selling partner-brand goodsJoyoung, Huawei, Xiaomi, Jinlongyu, AodongProduct margin
Channel distributionWholesale to platform self-operated channels and distributorsJD.com, Vipshop, othersDistribution margin
Platform cooperation / content commerceContent marketing and live-stream on Douyin, Xiaohongshu, Kuaishou, WeChat Channels; cross-platform conversion paths (e.g., Xiaohongshu content to JD/Tmall conversion; Douyin live-stream to JD/Tmall repurchase)Same brandsProduct margin (fee components not disclosed)
One-stop brand servicesFront-end brand positioning, visual identity and packaging design; mid-end store operations and campaigns; back-end 24/7 customer serviceBrand clients—
Health products (planned)Health food, health-care products, medical aids; possible own-brand health products "at the appropriate time"PlannedNot yet launched
Cross-border e-commerce (planned)Stated exploration in the FY2026 Chairman's StatementPlannedNot yet launched

Property

OfferingStatus at 31 Mar 2026
Completed residential/commercial units held for saleApprox. 284,300 sqm. FY2026 contracted sales RMB420m on 85,000 sqm (approx. RMB5,085/sqm).
Investment properties (leasing)Leasable area reduced by the On Tai disposal and asset sales. FY2026 fair-value loss RMB206.6m.
Property management servicesRevenue RMB17.7m in FY2024; later years not separately retrieved.
ProjectLocationUsePlanned GFA (sqm)Equity shareStatus (Mar 2024)
Yihe Emerald MansionYuxi, YunnanResidential/Commercial456,507100%Expected 2026
Boya BinjiangFoshan, GuangdongResidential/Commercial909,59851%Expected 2024
Wei Ming 1898Kaifeng, HenanResidential/Commercial384,569100%Expected 2024
Zijing MansionChongqingResidential/Commercial209,632100%Completed
BoyaChongqingResidential/Commercial499,94770%Completed
Jiangshan MingmenChongqingResidential/Commercial706,601100%Completed
YuelaiChongqingResidential/Commercial425,94770%Completed
Boya City PlazaChengdu, SichuanCommercial/Office144,00851%Completed
Wei Ming MansionHangzhou, ZhejiangResidential/Commercial193,736100%Completed
Shanshui NianhuaWuhan, HubeiResidential/Commercial278,43770%Completed
580 ProjectChongqingResidential/Commercial613,530100%Not commenced
Lianhu JinchengEzhou, HubeiResidential/Commercial394,17590%Not commenced (Ezhou Jinfeng sold May 2024)

Legacy project list at 31 March 2024 (12 projects in 8 cities):

The Yuxi, Kaifeng, Chongqing (several), Hangzhou (Zhejiang Resources) and Wuhan (Tianhe Jincheng) entities were among the 16 On Tai subsidiaries injected into the partnership in August 2025. A project-level list of what remains after the disposal was not published in the material retrieved.

Asset management

OfferingDetail
SFC Type 9 licensed managerPeking University Resources Asset Management Ltd (licence April 2023)
Hong Kong Gateway / Stock Connect Special Opportunities Return LP FundInvestment manager since Dec 2023
Suzhou Aoze JV (8 Aug 2024)Real-estate and healthcare NPA investment
Suzhou Aoze partnership (7 May 2025)Debt restructuring and development of the group's former property projects; group is subordinated LP

Pending new businesses (announced 29 July 2026)

TargetBusinessConsiderationReported net assets (end-2025)
LN Future Building Materials Co. Ltd (Tanzania), 100%Major East African aluminium-profile manufacturer: casting, extrusion, surface treatment, QCUS$4.17mApprox. RMB283m
China Boda Technical Group Ltd (Tanzania), 99%Waste-battery recycling, recycled lead, lead-acid battery production and saleUS$2.42mApprox. RMB165m

Financial Narrative

Sources and conventions:

  • Sources: company annual reports and results announcements for FY2023 (AR 2022/23), FY2024 (results announcement 28 Jun 2024), FY2025 (results 30 Jun 2025) and FY2026 (AR 2025/26). FY2022 figures come from the FY2023 annual report comparatives.

  • FY2022 is 15 months.

  • Rows marked "aggregator" come from stockanalysis.com and use that site's definitions.

Income statement

Notes on the income statement:

  • Pre-tax profit for FY2022, FY2025 and FY2026 is derived as net profit plus tax.

  • FY2025 "other gains" (RMB327m) and selling/admin expenses come from the Reuters/PUBT summary of the FY2025 results.

  • FY2024 adjusted to the post-consolidation share count would be about -32.96 RMB cents (analyst adjustment).

  • Data conflicts:

    • The aggregator shows FY2022 revenue of RMB9,440m and net income of RMB1,208m. The annual report shows RMB11,799.6m and RMB1,509.5m (15 months). The aggregator appears to use a different period basis. The filing figures are used here.

    • FY2026 gross profit is RMB115.1m in the MD&A versus RMB88.7m on the aggregator.

    • FY2025 gross loss is RMB53.0m in the MD&A versus RMB60.5m on the aggregator.

Margins and growth (%)

Revenue CAGR FY2023–FY2026 (three 12-month years) is -33.1% a year (RMB5,174.9m to RMB1,551.5m). A five-year CAGR is not meaningful because FY2022 is a 15-month period.

Trend commentary. Group revenue has fallen 87% from the 15-month FY2022 peak. This reflects three things: the forced unwinding of the IT distribution business after litigation by Peking Founder and a creditor; the run-down of property deliveries; and the deconsolidation of subsidiaries.

The bottom line has swung between large profits and large losses almost entirely on non-operating items:

  • disposal gains (RMB3.9bn in FY2022, RMB1.2bn in FY2024, RMB2.16bn in FY2026);

  • guarantee and litigation provisions (RMB744m in FY2024 and about RMB1.6bn of other losses in FY2025);

  • land resumption losses (RMB336.6m in FY2024);

  • property impairments and fair-value moves.

On the aggregator's operating-income definition, which excludes these items, the group has made an operating loss in every year shown. The operating loss in FY2026 was RMB184.5m, an 11.9% negative margin. This is the crucial point: the FY2026 headline profit is an accounting consequence of deconsolidation, not evidence of earnings power.

Balance sheet

Notes on the balance sheet:

  • FY2025 equity attributable to owners was a deficit.

  • FY2025 and FY2026 net current assets are not quantified in retrieved text. The current ratios of 0.88 and 1.33 imply negative and positive working capital respectively.

  • Goodwill relating to pharma (RMB38.6m) was impaired in FY2026, implying that pharma goodwill is now nil or near nil.

  • Data conflict on FY2023 borrowings: the FY2023 Annual Report shows RMB1,919.6m (RMB1,325.9m current). The comparative restated in the FY2024 results shows RMB2,339.6m (RMB1,745.9m current, RMB593.7m non-current). The annual-report figure is used above. The restated figure implies FY2023 net debt of RMB1,613.7m.

  • NAV per share: the FY2026 AR reports 64.85 RMB cents (total equity including NCI divided by shares). On owners' equity, NAV per share is about 21.5 RMB cents, consistent with etnet's RMB0.215.

Cash flow

Notes:

  • Cash and restricted cash fell RMB354.6m in FY2026, partly from deconsolidation of the On Tai group's cash.

  • Capex for FY2024 is also given by the company as RMB11.8m (additions to PP&E and investment properties).

  • No buybacks were disclosed in any year.

Cash commentary. The group has burned operating cash in every year for which data is available, despite large working-capital releases from property inventory (inventory change of RMB2.6bn in FY2022 and RMB0.6bn in FY2025 per the aggregator). Equity raises have been tiny: HK$34.2m from the May 2024 subscription, plus option exercises. Liquidity has instead come from asset disposals, debt-for-equity settlements and deconsolidations.

Ratios

Notes:

  • ROE on owners' equity is not meaningful because owners' equity was negative at end-FY2022 and end-FY2025.

  • Interest coverage includes one-off gains and losses and is distorted.

  • ROIC is not meaningful given negative operating income in every year.

  • Net debt/EBITDA is not meaningful because EBITDA was negative in FY2024–FY2026. In FY2026 the group was in net cash of RMB177.4m.

  • Cash conversion cycle components (receivable, inventory and payable days) were not disclosed in retrieved material. In FY2024, trade receivables were RMB224.6m and trade payables RMB1,285.6m, with 61% of payables aged over six months, which signals stretched payables in the property business.

Inflection assessment.

  • FY2026 is the cleanest balance sheet since at least FY2022: gearing of 0.07x, a current ratio of 1.33x, no mortgage guarantees and no PUD commitments.

  • But the asset base has shrunk by 79% since FY2022 (to RMB3.85bn), owners' equity is only RMB589.7m, and NCI (RMB1.19bn) still exceeds owners' equity.

  • Total liabilities of RMB2.07bn include RMB979.7m of other payables and accruals. The September 2026 Supreme People's Court judgment adds a fresh liability of about RMB187m plus interest since December 2019.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsKey entities / brands

Medical and pharmaceutical retail

Chinese medicine, pharmaceutical retail, TCM consultation, beauty and dermatology clinics, online pharmacy, O2O delivery

Wuhan Yekaitai Pharmaceutical Chain Co., Ltd.; Ye Kai Tai Health app; ResoHealth FZCO (Dubai)

E-commerce and distribution

Online sale of appliances, consumer electronics and health food; distribution

Partner brands Joyoung, Huawei, Xiaomi, Jinlongyu, Aodong

Property development

Sale of residential and commercial units (run-off since Aug 2025)

Remaining completed inventory (approx. 284,300 sqm held for sale)

Property investment and management

Leasing of retained properties; property management services

—

Revenue by Segment

SegmentFY2022FY2023FY2024FY2025FY2026

Medical and pharmaceutical retail revenue (CNY Mn)

0087.8190.8155.1

E-commerce and distribution revenue (CNY Mn)

7,371.01,907.2621.4711.9936.1

Property development revenue (CNY Mn)

4,332.83,219.7558.2605.2377.3

Property investment and management revenue (CNY Mn)

95.847.9173.6110.783.0

Total revenue (CNY Mn)

11,799.65,174.91,441.01,618.51,551.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Results by Segment

SegmentFY2022FY2023FY2024FY2025FY2026

Medical and pharmaceutical retail result (CNY Mn)

003.8-0.1-54.7

E-commerce and distribution result (CNY Mn)

40.2-55.430.813.529.6

Property development result (CNY Mn)

1,078.01,851.9-117.3-2,184.32,211.8

Property investment and management result (CNY Mn)

-335.085.0-29.8-133.0-440.6

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2024FY2025FY2026

E-commerce segment margin (%)

5.01.93.2

Pharma segment margin (%)

4.3-0.1-35.3

E-commerce revenue YoY growth (%)

-67.414.631.5

Pharma revenue YoY growth (%)

0117.3-18.7

Property development revenue YoY growth (%)

-82.78.4-37.7

Property investment revenue YoY growth (%)

262.4-36.2-25.0

E-commerce share of revenue (%)

43.144.060.3

Pharma share of revenue (%)

6.111.810.0

Property development share of revenue (%)

38.737.424.3

Property investment share of revenue (%)

12.06.85.3

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (CNY Mn)

11,799.65,174.91,441.01,618.51,551.5

Gross profit (CNY Mn)

1,154.4760.8130.8-53.0115.1

Other gains and losses net (CNY Mn)

5,775.61,992.7515.9327.0—

Gains on disposal of subsidiaries (CNY Mn)

3,928.6306.51,202.7—2,163.3

Selling and administrative expenses (CNY Mn)

743.9314.3234.7355.4259.5

Other expenses and losses (CNY Mn)

1,578.9647.0842.71,614.2173.9

Finance costs (CNY Mn)

548.5266.5112.4126.778.5

Operating income aggregator (CNY Mn)

-17.3-2.2-459.4-2,156.0-184.5

EBITDA aggregator (CNY Mn)

—2.6-454.1-2,149.1-176.6

Pre-tax profit (CNY Mn)

241.61,596.5-742.8-2,456.51,643.8

Income tax expense (CNY Mn)

675.3577.77.563.1-1.2

Net profit total (CNY Mn)

-433.71,018.9-750.2-2,519.61,645.0

Net profit to owners (CNY Mn)

1,509.5966.7-785.6-2,339.91,783.5

Non-controlling interests (CNY Mn)

-1,943.252.235.4-179.7-138.5

Basic EPS as reported (MYR Bn cents)

23.5313.71-8.24-85.9965.15

Diluted EPS as reported (MYR Bn cents)

23.5313.71-8.24-85.9965.15

Dividend per share (MYR Bn cents)

00000

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin (%)

9.814.79.1-3.37.4

Operating margin aggregator (%)

-0.20.0-31.9-133.2-11.9

EBITDA margin aggregator (%)

—0.1-31.5-132.7-11.4

Net margin total profit (%)

-3.719.7-52.1-155.7106.0

Revenue growth YoY (%)

—-56.1-72.212.3-4.1

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (CNY Mn)

18,267.412,648.611,522.910,212.83,849.4

Total liabilities (CNY Mn)

15,878.910,113.19,015.29,815.72,074.2

Total equity (CNY Mn)

2,388.52,535.62,507.7397.11,775.2

Equity attributable to owners (CNY Mn)

-462.11,461.51,034.5-1,256.2589.7

Non-controlling interests (CNY Mn)

2,850.61,074.11,473.21,653.31,185.5

Cash and restricted cash (CNY Mn)

683.9725.9904.1661.1306.5

Total borrowings (CNY Mn)

4,518.01,919.61,748.11,767.3129.1

Borrowings due within one year (CNY Mn)

3,497.91,325.9636.41,566.151.7

Borrowings due after one year (CNY Mn)

1,020.1593.71,111.7201.277.4

Net debt (CNY Mn)

3,834.11,193.7844.01,106.2-177.4

Goodwill (CNY Mn)

—038.6——

Other intangible assets (CNY Mn)

—013.8——

Properties for sale (CNY Mn)

—9,213.57,422.0——

Investment properties (CNY Mn)

—1,230.61,387.3——

Net current assets (CNY Mn)

—1,689.62,015.5——

Contingent mortgage guarantees (CNY Mn)

3,136.71,339.7915.3850.20

Capital commitments PUD (CNY Mn)

1,829.02,133.21,655.9766.00

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow aggregator (CNY Mn)

-528.7-108.0-126.8-31.0—

Capital expenditure aggregator (CNY Mn)

-7.1-7.5-11.3-17.2—

Free cash flow aggregator (CNY Mn)

-535.8-115.5-138.1-48.2—

Dividends paid (CNY Mn)

00000

Share buybacks (CNY Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE on average total equity (%)

—41.4-29.7-173.5151.4

ROA on average total assets (%)

—6.6-6.2-23.223.4

Current ratio (x)

1.191.181.260.881.33

Gearing total borrowings to total equity (x)

1.890.760.704.450.07

Interest coverage PBT plus finance costs (x)

1.447.0-5.6-18.421.9

Asset turnover (x)

—0.330.120.150.22

Revenue by Region

RegionFY2023FY2024

Mainland China revenue (CNY Mn)

5,174.91,431.8

Singapore revenue (CNY Mn)

09.1

Hong Kong revenue (CNY Mn)

00

Segment Overview — Medical and pharmaceutical retail

SegmentMainland China (CNY Mn)Singapore (CNY Mn)Total (CNY Mn)

Medical and pharmaceutical retail

78.79.187.8

E-commerce and distribution

621.40621.4

Property development

558.20558.2

Property investment and management

173.60173.6

Total

1,431.89.11,441.0

Locations

LocationFY2023FY2024

Mainland China non-current assets (CNY Mn)

1,498.81,626.0

Hong Kong non-current assets (CNY Mn)

0.21.3

Singapore non-current assets (CNY Mn)

02.0

Share Price History

DatePrice (HKD)Note

29 Dec 2023

0.40 (equivalent)

Pre-consolidation HK$0.10 × 4 (option grant date)

2 Sep 2022

0.476 (equivalent)

Pre-consolidation HK$0.119 × 4 (option grant date)

52-week low (as of mid-2026)

0.141

Tiger Brokers quote page

18 Jun 2026

0.41

Day after profit alert (+15.5%)

22 Jun 2026

0.485

Peak close in run-up (52-week high approx. 0.50)

17 Jul 2026

0.315

Post-results fade

31 Jul 2026

0.345

stockanalysis

9 Oct 2026

0.285

Latest close retrieved (etnet)

Valuation Snapshot

MultipleValueBasis / caveat

Market capitalisation

Approx. HK$780m

2,737.4m shares × HK$0.285

Trailing P/E

Approx. 0.4x

EPS RMB0.6515; not meaningful, driven by one-off disposal gains

P/B (owners' equity)

Approx. 1.2x

Owners' equity RMB589.7m (approx. HK$640m)

EV

Approx. RMB1.0bn (approx. HK$1.1bn)

Market cap + debt RMB129.1m + NCI RMB1,185.5m - cash RMB306.5m

EV/Sales

Approx. 0.65x

FY2026 revenue RMB1,551.5m

Debt Maturity Profile

Maturity bucketAmount (CNY Mn)

Within 1 year

51.7

1–2 years

0

2–3 years

77.4

Total

129.1

Analyst Conclusions

Management guidance

No quantitative guidance. Management's qualitative outlook for FY2027:

  • e-commerce: continued growth and an expanded health-product range;

  • pharma: recovery via digital channels;

  • property: orderly asset disposals;

  • asset management: prudent development.

The interim results for the six months to 30 September 2026 are due by the end of November 2026.

Consensus

None available (no coverage).

Bull case

  1. Clean slate with net cash. Gearing of 0.07x, net cash of RMB177m and no guarantees or PUD commitments give management freedom to redeploy capital for the first time since 2020.

  2. E-commerce operating leverage. If revenue keeps compounding at about 30% (FY2026: +31.5%) and own-brand health products lift margins from 3% towards 5–6%, the segment could plausibly earn RMB50–70m. That would be a meaningful figure against a market capitalisation of about HK$780m. This is illustrative, not a forecast.

  3. Bargain acquisitions. The Tanzanian targets' reported net assets (about RMB448m) far exceed their US$6.59m price. If those assets are bona fide and income-producing, completion could add book value well above cost and create a new earnings stream.

Bear case

  1. No earnings engine. The group has posted operating losses in five consecutive reporting periods, and the FY2026 "profit" came entirely from deconsolidation. Pharma is losing money and shrinking, and e-commerce margins are too thin to cover head-office costs.

  2. New liabilities against a small equity base. The September 2026 SPC judgment (RMB187m plus about 6.5+ years of interest) could consume a large share of the RMB306.5m cash balance and roughly a third or more of owners' equity, depending on accounting treatment and enforcement.

  3. Governance and capital-allocation risk. Insider-controlled ownership, recurring counterparties (Suzhou Aoze), an abandoned JV and an unrelated pivot into African aluminium and lead recycling do not show disciplined capital allocation. The 2021 misappropriation episode sets a low trust baseline.

Catalysts and monitorables (next 12 months)

ItemExpected timingWhat to watch
H1 FY2027 interim results (to 30 Sep 2026)By end-Nov 2026Accounting for the SPC judgment; e-commerce growth; pharma losses; cash level
Completion of the Tanzanian acquisitionsWithin approx. 3 months of 29 Jul 2026 (approx. late Oct 2026)Purchase-price allocation; any bargain-purchase gain; target audited accounts
Enforcement or settlement of the Ping An Huitong judgmentQ4 2026–2027Cash outflow quantum; revival of the RMB24.36m follow-on claim
Board changes after Hou Ruilin's exitOngoingShareholding changes in SFO disclosures; any change in insider control
Remaining property inventory sell-downOngoingASP trend versus RMB5,085/sqm; investment-property fair values
Pharma store count and clinic expansionInterim and annual reportsStabilisation versus further closures
Partnership (On Tai) outcomesOngoingAny claw-back, top-up or recourse to the group as subordinated LP
FY2027 annual resultsJun 2027First clean year without development operations

Concluding analyst verdict

Peking University Resources has done one important thing well. It has escaped the property-development liabilities that pushed its owners' equity into deficit twice in four years.

The August 2025 partnership did several things at once:

  • deconsolidated defaulted loans, mortgage guarantees and the legacy Huzi guarantee provisions;

  • produced a RMB1.65 billion accounting profit;

  • cut borrowings from RMB1.77 billion to RMB129 million.

On balance-sheet risk alone, FY2026 marks a true inflection.

What remains, however, is not yet a business with demonstrated earnings power. The e-commerce segment is growing quickly but earns 3 cents per yuan of sales. The Ye Kai Tai pharmacy chain, bought in 2023 as the strategic growth pillar, has lost 18 stores in two years, swung to a loss and had its goodwill written off. On the aggregator's definition, consolidated operating income has been negative in every period for five years. Meanwhile the September 2026 Supreme People's Court ruling has added a nine-figure liability. Against roughly RMB590 million of owners' equity and RMB307 million of cash, it is material.

Capital allocation since the clean-up has not built confidence:

  • a metals-trading JV announced and abandoned within four months;

  • a Dubai digital-health venture;

  • an AI partnership;

  • two Tanzanian industrial acquisitions at prices far below reported book value.

The last of these may prove value-accretive, but it raises legitimate questions about asset quality, related parties and strategic fit. Insider concentration of about 45% across executive directors at the last disclosure, and the 2021 misappropriation history, warrant a governance discount.

At about HK$0.285 the market already treats the FY2026 profit as non-recurring. The shares trade near 1.2x owners' book value and about 0.65x EV/sales, with no dividend and no coverage. We regard the equity as a high-risk special situation rather than an investable operating story. Re-rating would require a clean H1 FY2027 that contains the SPC liability, sustained profitable e-commerce growth, pharma stabilisation and transparent integration of the Tanzanian assets. Until then, the risk/reward is asymmetric to the downside.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleFirst appointedCommitteesNotes

Mr Wong Kai Ho (黃啓豪)

Chairman, Executive Director

2021

Nomination (Chair), Remuneration

Largest shareholder (22.32% as of May 2024); company secretary until 11 Jul 2022; holds 2.575m options

Mr Huang Zhuguang (黃柱光)

Executive Director

2021—

Authorised representative; 11.66% with connected persons (May 2024)

Mr Xia Ding (夏丁)

Executive Director; Co-CEO; COO

30 Aug 2024

—

President of several subsidiaries; holds 5.75m options

Mr Hou Ruilin (侯瑞林)

Executive Director

2023—

Resigned 14 Sep 2026; 10.61% holder (May 2024)

Ms Xiong Yan (熊妍)

Executive Director

Sep 2026

——

Mr Chin Chi Ho, Stanley (錢志浩)

INED

2021

Audit (Chair), Remuneration

Financial expertise

Ms Xu Nan (徐楠)

INED

30 Aug 2024

Audit, Nomination

Only female director

Prof Cheung Ka Yue (張嘉裕)

INED

30 Sep 2024

Remuneration (Chair), Audit, Nomination

—

Executive Leadership Team

NameTitleNotes

Mr Shi Lei (石磊)

Co-Chief Executive Officer

CEO since at least FY2023

Mr Xia Ding

Co-CEO and COO

See above

Mr Jiang Xiaoping (蔣小平)

Deputy CEO; president of several subsidiaries

5.5m options outstanding

Ms Zhang Jiabo (張佳博)

Company Secretary

Appointed 30 Jan 2026 (replaced Ms Leung Mei King)

CFO

Not publicly disclosed in retrieved material

—

Governance Detail

Band (MYR Bn)Number

0 – 1,000,000

1

2,000,000 – 3,000,000

1

Major Shareholders

HolderShares% of issued

Wong Kai Ho

611,104,03922.32

Huang Zhuguang and connected persons

319,203,74311.66

Hou Ruilin

290,307,78210.61

Wu Wenbo (伍文波)

175,000,0006.39

Chen Mengyi (陳夢怡)

175,000,0006.39

Top-5 total

1,570,615,564

57.37

Governance Detail by Participant

ParticipantShares (m)%

格理昂證券有限公司

61922.60

Everbright Securities Investment Services (HK)

33912.39

UOB Kay Hian (HK)

1124.11

HSBC

95.73.50

Maybank Securities (HK)

53.71.96

Guotai Junan Securities (HK)

52.41.91

Competitive Landscape

Competitors by Segment

SegmentCompetitorPositioning vs PKU Resources

Pharma retail (national chains)

Dashenlin (大參林)

National-scale chain; orders of magnitude larger

Pharma retail

Yifeng Pharmacy (益豐藥房)

Same

Pharma retail

LBX Pharmacy (老百姓大藥房)

Same

Pharma retail

Yixintang (一心堂)

Same

Pharma retail / TCM heritage brands

Beijing Tong Ren Tang (北京同仁堂)

Time-honoured TCM peer cited by the company

Pharma retail / TCM heritage brands

Hangzhou Huqingyutang (胡慶餘堂)

Same

Pharma retail / TCM heritage brands

Guangzhou Chan Li Chai (陳李濟)

Same

Pharma retail (regional, Hubei)

Jointown (九州通) retail operations and local Wuhan independents

Local share competition (no data)

E-commerce TP / brand operation

Baozun (寶尊電商)

Largest listed brand e-commerce partner; fee-based plus distribution

E-commerce TP / brand operation

Ruoyuchen (若羽臣)

Brand operation plus own brands

E-commerce TP / brand operation

Lily & Beauty (麗人麗妝)

Beauty-focused TP

Distribution (legacy IT)

Digital China (神州數碼)

Largest China IT distributor; PKU exited traditional IT distribution

Property (run-off)

Numerous PRC developers

Irrelevant to forward thesis

Peer Comparison FY2026

CompanyLatest FY revenueRevenue growthMargin indicator

PKU Resources (FY2026, MYR Bn)

1.55bn

-4.1%

Gross 7.4%; operating approx. -11.9% (aggregator)

Dashenlin (FY2024, MYR Bn)

Approx. 24–25bn

——

Yifeng Pharmacy (FY2024, MYR Bn)

Approx. 24bn

——

Baozun (FY2024, MYR Bn)

Approx. 9bn+

——

Recent Developments

All material items found are included.

Company Snapshot

$215.8M

Revenue

512

Employees

1991

Founded

Causeway Bay, Hong Kong

Headquarters

SWOT Analysis

Strengths

  • Deleveraged balance sheet: borrowings fell from RMB1,767.3m (FY2025) to RMB129.1m (FY2026); gearing from 4.45x to 0.07x (FY2026 AR).
  • Net cash position: cash and restricted cash of RMB306.5m against debt of RMB129.1m, i.e. net cash of RMB177.4m (FY2026).
  • Contingent liabilities removed: mortgage guarantees went from RMB850.2m to nil, and PUD commitments from RMB766m to nil (FY2026 AR).
  • Growing e-commerce segment: revenue +31.5% to RMB936.1m and segment profit more than doubled to RMB29.6m (FY2026).
  • Heritage brand: Ye Kai Tai is recognised as a China Time-honored Brand (1994) and Wuhan Famous Trademark (2014) (FY2024 results).
  • Regulated asset-management platform: SFC Type 9 licence since April 2023, already used to execute the group's own restructuring (FY2026 AR).

Weaknesses

  • No operating profitability: aggregator operating losses in each of FY2022–FY2026, including RMB184.5m in FY2026.
  • Earnings quality: FY2026 profit (RMB1,645m) depended on RMB2,163.3m of disposal gains.
  • Pharma deterioration: revenue -18.7%, segment loss RMB54.7m and goodwill impairment RMB38.6m in FY2026, within about 2.5 years of an RMB81m acquisition.
  • Persistent operating cash burn: operating cash flow negative in every year with data (e.g., -RMB126.8m in FY2024; aggregator).
  • Minority interests exceed owners' equity: NCI of RMB1,185.5m versus owners' equity of RMB589.7m (FY2026).
  • Shrinking scale: revenue down 87% since FY2022 (15-month basis) and headcount down to 512.

Opportunities

  • Prescription-outflow and pharmacy-M&A policies (January 2026 Opinions; 15th Five-Year Plan) could favour a TCM-differentiated operator.
  • Content-commerce expertise (Douyin, Xiaohongshu) in an online retail market growing 8.6% a year (2025).
  • Possible bargain-purchase value in the Tanzanian targets: reported net assets of about RMB448m for US$6.59m consideration (July 2026 announcement).
  • Own-brand health products to lift e-commerce margins (FY2026 AR plans).
  • Asset-management fee income from third-party NPA mandates (Suzhou Aoze JV, August 2024).
  • Monetising the remaining 284,300 sqm of completed inventory if Chinese property prices stabilise.

Threats

  • Litigation: the Supreme People's Court judgment (16 Aug 2026) requires return of RMB187m plus interest since December 2019. A related RMB24.36m claim is stayed and may revive.
  • Pharmacy regulation: medical-insurance tightening and traceability rules raise compliance costs (effective 1 July 2025).
  • Property price deflation: ASP fell from RMB7,760/sqm (FY2024) to RMB5,085/sqm (FY2026).
  • Execution risk in unrelated diversification: African aluminium and lead-acid recycling, the latter carrying high environmental-compliance exposure.
  • Brand concentration: dependence on a few partner brands, whose terms or platform rules can change.
  • Governance and reputation: history of trading suspension (April 2021 to August 2022), misappropriation findings and auditor-driven restatement of interim revenue (FY2024).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
31 Mar 2025Supreme People's Court orders retrial in Ping An Huitong v Foshan PKU (RMB187m claim)Reopened a case the group had won on appeal
7 May 2025Partnership agreement with Suzhou Aoze and Chongqing Jingjiahui signedMechanism for property exit
26 Jun 2025Major-transaction circular and SGM notice publishedShareholder approval process
30 Jun 2025FY2025 results: revenue RMB1,618.5m (+12%); gross loss RMB53m; net loss RMB2,519.6m; owners' equity in deficitLow point of the cycle
16 Jul 2025SGM approves partnership / disposalClears restructuring
Jul 2025Disposal group deconsolidation process (MD&A refers to July disposal; completion 11 Aug)—
11 Aug 2025On Tai group injection completedGroup exits property development; defaulted loans and guarantees deconsolidated
27 Aug 2025AGM held; all directors attendedRoutine
9 Sep 2025Ping An Huitong files new RMB24.36m claim in Sanshui District CourtAdditional litigation exposure
19 Sep 2025Hangzhou Linghangxing disposal completed (approx. RMB1m)Clean-up
Oct 2025"Ye Kai Tai Health" app launched; ResoHealth FZCO established in DubaiDigital and international health push
28 Nov 2025Shows disposal gain in H1 FY2026
22 Dec 2025Chongqing Yuefeng (70%) disposal completedClean-up
9 Jan 2026Voluntary announcement: Trivitron Digital AI launched with Trivitron HealthcarePartnership
30 Jan 2026Company Secretary change (Leung Mei King to Zhang Jiabo)Governance
26 Mar 2026Tianjin Ruihesheng disposal completedClean-up
30 Mar 2026Discloseable transaction: non-ferrous metals trading JVDiversification attempt
14 Apr 2026Sanshui court stays the RMB24.36m new litigation pending retrialLitigation
17 Jun 2026Positive profit alert: FY2026 profit RMB1.4–1.8bnShare price rose up to 35% intraday on 18 Jun
18–22 Jun 2026Shares rose to approx. HK$0.485 (52-week high approx. HK$0.50)Market reaction
30 Jun 2026FY2026 results: revenue RMB1,551.5m (-4.1%); profit RMB1,645m; owners RMB1,783.5m; EPS RMB65.15 cents; no dividendTurnaround on one-offs
Jul 2026Shares fell back to HK$0.295–0.315 by mid-JulyMarket discounts one-off profit
24 Jul 20262025/26 Annual Report publishedFiling
29 Jul 2026Non-ferrous JV terminated; Tanzanian acquisitions announced (US$6.59m)Strategic pivot into industrial assets
16 Aug 2026Supreme People's Court retrial judgment against Foshan PKUNew liability
27–28 Aug 2026AGM circular: proposed re-appointment of CCTH; next-year audit fee estimated up to 2.2mGovernance
14 Sep 2026Executive Director Hou Ruilin resigns; Xiong Yan appointed Executive Director (nominal salary of 1)Board change; a 10.6% holder departs the board
28 Sep 2026Announcement of the SPC judgment: return RMB187m plus interest from 19 Dec 2019, plus costs; board discussing accounting treatmentMaterial adverse item for FY2027
9 Oct 2026Share price HK$0.285Below pre-profit-alert levels of mid-June

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue fell from CNY 11,799.6 Mn in FY2022 to CNY 1,551.5 Mn in FY2026.
Peking University Resources (Holdings) Company Limited — Income Statement: Revenue & Gross Profit
Series (CNY Mn)FY2022FY2023FY2024FY2025FY2026
Revenue11,799.65,174.91,4411,618.51,551.5
Gross profit1,154.4760.8130.8-53115.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.